A77 1726 increases IL-1 receptor antagonist (IL-1Ra) secretion in human synovial fibroblasts and articular chondrocytes in the presence of IL-1β
Figures are generally photos, graphs and static images that would be represented in traditional pdf publications.
Taken from "The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes"
Arthritis Research & Therapy 2004;6(3):R181-R189.
Published online 19 Feb 2004
Copyright © 2004 Palmer et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.Human osteoarthritis (OA) synovial fibroblasts (passage 2) and de-differentiated human OA articular chondrocytes (passage 7) were stimulated (closed symbols) or not (open symbols) with 1 ng/ml IL-1β alone or in combination with 50 μmol/l or 100 μmol/l A77 1726 for 48 hours. Freshly isolated normal human articular chondrocytes were stimulated (black columns) or not (white columns) with 100 μmol/l A77 1726 alone or in combination with 1 ng/ml IL-1β for 48 hours. A77 1726 was added 2 hours before stimulation with IL-1β. IL-1Ra concentrations in culture supernatants were measured using ELISA. Results are expressed as means ± SEM for three determinations in a representative experiment. Similar results were obtained with cells from three different donors (three OA samples) for synovial fibroblasts and three different donors (three OA samples) for de-differentiated chondrocytes. On freshly isolated chondrocytes, a stimulatory effect of A77 1726 was observed in cells from 12 (five normal adult, six OA and one normal paediatric sample) out of 18 different donors. *< 0.05 versus control; < 0.05 versus IL-1β alone.